诺诚健华：公司预计2025年度首次实现扭亏为盈

Core Viewpoint - The company, Nocera Biopharma, is progressing smoothly in pipeline advancement and commercialization, with no operational difficulties reported. It anticipates achieving profitability for the first time in 2025, with significant revenue growth expected [1] Financial Performance - The company forecasts a total revenue of approximately RMB 2.365 billion for the fiscal year 2025, representing a growth of around 134% compared to the previous year [1] - The net profit attributable to the parent company is projected to be around RMB 633 million for 2025 [1]